Improvement after a supplement is not the same as a comparative result
Start with the comparison. A before-and-after change alone cannot isolate the contribution of an ingredient.
Ginkgo
Selected research topic
Glucose and metabolic health
The confirmed comparison studies tested several ingredients together. They cannot isolate the effect of this ingredient.
Some findings concern patients or people with a deficiency.
- Publications for this topic
- 4
- Human comparison publications
- 1
- Publications needing review
- 3
Findings in the studies
HbA1c
- A better result than the comparison group was reported.
Several ingredients were tested together, so this ingredient’s individual effect is unknown.
What the comparison group used was not confirmed.
Patient group · Combination studyMeasurement and study conditions
- Study type
- Randomized controlled trial: subjects were randomly assigned to groups for comparison.
- Study population
- Human participants · Patient group
- Ingredients tested
- Ingredient combination
- How results were compared
- Results were compared between groups.
- Measurement time
- Not confirmed.
This result is held for interpretation. That does not mean research found no effect.
Outcome groups needing additional review (2)
- improvement of MetS · Distinct papers needing additional review: 1Evidence criteria check: 1
- metabolic syndrome · Distinct papers needing additional review: 1Evidence criteria check: 1
One paper can appear under multiple measured outcomes or review reasons, so these counts should not be added together.
Representative outcome and study details
Partial research summary
Human studies reported between-group improvement in HbA1c.
These conditions come from related studies and may not describe a single paper.
single- and combination-ingredient studies · Individual ingredient effects cannot be separated · Human studies · Includes patient groups · between-group comparison · within-group comparison
2 publications linked to this result (1 awaiting review included)
- Study conditions differ; results are shown descriptively and are not pooled.
- Combination, formula, or class studies do not isolate this ingredient or establish synergy.
- Some publications have not cleared source or interpretation review.
- Some papers could not be reviewed, so this summary covers only findings that could be confirmed.
Data coverage and detailed study classifications
Paper counts are separated by research topic below. One paper may contribute to multiple findings.
Analysis status: Public-ready
Ingredient analysis date:
How the grade was determined: C
The 8.4 evidence score includes 1 independent human studies and 1 clinical studies in the representative benefit area. The C tier remains conservative because of limited repetition across independent human clinical studies, too few clinical findings with an explicit effect direction.
The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.
Papers linked to this ingredient overall: 115
Papers linked to this topic 4 · distinct papers 4 · papers with a confirmed human comparison 1 · papers needing additional review 3
A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.
- HbA1c: Sources represented in this measurement group: 2 · Distinct papers with human comparisons for this outcome: 1
- improvement of MetS: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
- metabolic syndrome: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
What the research found
HbA1c
The study reported improvement in this measurement.
Controlled study in people · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
Between-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
HbA1c
The study needs further checking before its result can be interpreted.
Controlled study in people · Single ingredient · Patient group
Within-group comparison
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
improvement of MetS
The study needs further checking before its result can be interpreted.
Review · Unknown intervention · Unspecified population
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
metabolic syndrome
The study needs further checking before its result can be interpreted.
Review · Unknown intervention · Patient group
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
How to read research findings
How should I read research findings?
Research guidesNo clear difference and an uninterpretable result are different
A reported null comparison contains a result. An abstract without an interpretable comparison leaves a question unresolved.
Paper counts and study counts are different
Count original research separately from research that reanalyzes it. Publication volume is neither replication nor a quality rating.
Side effects and combination findings
Findings from this ingredient alone are shown separately from those involving another supplement or medication.
No reviewed caution rules are available yet. Reported caution findings are shown below.
Findings to review with care
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Side effects reported with this ingredient alone
Symptoms or adverse events reported in studies without another active ingredient.
liver injury1 papers
Hepatotoxicity observed in rodent studies of a commercially available unfinished GbE product.Animal studies · Animal studyembryotoxicity1 papers
Ginkgo biloba leaf extract contains ginkgolic acids that cause embryotoxicity, cytotoxicity, neurotoxicity, and enzyme inhibition.Cell studies · Systematic reviewneurotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may have adverse effects on the nervous system.Human studies · Systematic reviewnephrotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may exhibit nephrotoxicity.Human studies · Systematic reviewhepatotoxicity1 papers
Ginkgolic acids can induce significant hepatic damage by promoting cellular apoptosis, oxidative stress, and disruption of metabolic processes.Human studies · Systematic reviewendotoxins and ginkgolic acids toxicity1 papers
The review reports that endotoxins and ginkgolic acids present in Ginkgo biloba are identified as dominant toxic components.Human studies · Systematic reviewDropout due to adverse events1 papers
Meta-analysis showed dropout rates due to side effects were significantly lower with Ginkgo biloba than placebo (OR = 1.72, 95% CI [1.06, 2.80]), indicating a favorable safety profile.Human studies · Meta-analysisdermatotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may have adverse effects on the skin.Human studies · Systematic reviewCautions reported with another supplement or medication
These studies reported worsening outcomes, reduced absorption, or other cautions with combined use. They do not predict an individual's outcome.
CilostazolCoadministration of Ginkgo biloba with cilostazol significantly potentiated the prolongation of bleeding time compared to individual doses.